Indian pharma companies are expanding in the US through acquisitions to navigate regulations, diversify portfolios, and ...
To read all of these articles and more, visit centerforbiosimilars.com.
Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...
Celltrion and Formycon with Fresenius Kabi launched their respective ustekinumab biosimilars (Steqeyma and Otulfi), joining 4 ...
Amneal announced FDA acceptance of its Biologics License Application (BLA) for two proposed denosumab biosimilars ...
Omlyclo is used for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, ...
Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...
Celltrion Inc. is on a biosimilar roll with the U.S. FDA this month, having gained clearance of Stoboclo and Osenvelt as products referencing Amgen Inc.’s biologic, denosumab (Prolia, Xgeva), along ...
Achieving cost sustainability in inflammatory bowel disease (IBD) care requires expanding access to cost-effective treatments ...
Spherico and the Syneos Health Value & Access team interviewed 25 pharmacy or medical directors. The fifth annual Payer Survey gives insight and understanding from national and regional payers, as ...
The FDA has approved Stoboclo (denosumab-bmwo), a biosimilar to Prolia (denosumab), and Osenvelt (denosumab-bmwo), a biosimilar to Xgeva (denosumab).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback